Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy

Practical Radiation Oncology

Volumn 5, Issue 5, 2015, Pages 338-342

  McDonald, Andrew M ^a   Baker, Christopher B ^b   Popple, Richard A ^a   Cardan, Rex A ^a   Fiveash, John B ^a  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; DOSIMETRY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION DOSE INHOMOGENEITY; TOMOTHERAPY; URETHRA STENOSIS; URINARY FREQUENCY; VOLUMETRIC MODULATED RADIATION THERAPY; HYPOFRACTIONATED RADIOTHERAPY; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; URETHRAL STRICTURE;

DOSE FRACTIONATION; DOSE HYPOFRACTIONATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; URETHRAL STRICTURE;

EID: 84940954417     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2015.02.010     Document Type: Article

References (14)

1. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial [published correction appears in JAMA. 2008;299:899-900]. JAMA 2005, 294:1233-1239.
2. Viswanathan A.N., Yorke E.D., Marks L.B., Eifel P.J., Shipley W.U. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010, 76:S116-S122. [Suppl.].
3. Pollack A., Walker G., Horwitz E.M., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013, 31:3860-3868.
4. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
5. US Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE): version 4.0. June 14, 2010 Available at:, Accessed September 1, 2014. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf.
6. Kupelian P.A., Thakkar V.V., Khuntia D., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468.
7. Hoffman K.E., Voong K.R., Pugh T.J., et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial. Int J Radiat Oncol Biol Phys 2014, 88:1074-1084.
8. Vesprini D., Sia M., Lockwood G., et al. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:e415-e421.
9. McCammon R., Rusthoven K.E., Kavanagh B., Newell S., Newman F., Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:413-420.
10. RTOG 0415 protocol information: A phase III randomized study of hypofractionated 3DCRT/IMRT versus conventionally fractionated 3DCRT/IMRT in patients treated for favorable-risk prostate cancer. Radiation Therapy Oncology Group 2010 Available at:, Accessed September 1, 2014. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0415.
11. Ishiyama H., Kitano M., Satoh T., et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: An analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009, 75:23-28.
12. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
13. Ghadjar P., Zelefsky M.J., Spratt D.E., et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2014, 88:339-344.
14. Vainshtein J., Abu-Isa E., Olson K.B., et al. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: Implications for focal therapy. Radiat Oncol 2012, 7:82.